296 related articles for article (PubMed ID: 21918854)
21. Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.
Riahi A; Kharrat M; Ghourabi ME; Khomsi F; Gamoudi A; Lariani I; May AE; Rahal K; Chaabouni-Bouhamed H
Clin Genet; 2015 Feb; 87(2):155-60. PubMed ID: 24372583
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
23. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
[TBL] [Abstract][Full Text] [Related]
24. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
25. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.
Machackova E; Foretova L; Lukesova M; Vasickova P; Navratilova M; Coene I; Pavlu H; Kosinova V; Kuklova J; Claes K
BMC Cancer; 2008 May; 8():140. PubMed ID: 18489799
[TBL] [Abstract][Full Text] [Related]
26. Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
Negura L; Uhrhammer N; Negura A; Artenie V; Carasevici E; Bignon YJ
Fam Cancer; 2010 Dec; 9(4):519-23. PubMed ID: 20567915
[TBL] [Abstract][Full Text] [Related]
27. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
[TBL] [Abstract][Full Text] [Related]
28. Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
Zhang Y; Wu H; Yu Z; Li L; Zhang J; Liang X; Huang Q
BMC Cancer; 2022 Aug; 22(1):842. PubMed ID: 35918668
[TBL] [Abstract][Full Text] [Related]
29. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
[TBL] [Abstract][Full Text] [Related]
31. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer.
Cavallone L; Arcand SL; Maugard CM; Nolet S; Gaboury LA; Mes-Masson AM; Ghadirian P; Provencher D; Tonin PN
Fam Cancer; 2010 Dec; 9(4):507-17. PubMed ID: 20694749
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific.
Cifuentes-C L; Rivera-Herrera AL; Barreto G
Colomb Med (Cali); 2019 Sep; 50(3):163-175. PubMed ID: 32284662
[TBL] [Abstract][Full Text] [Related]
36. A novel BRCA1 duplication and new insights on the spectrum and frequency of germline large genomic rearrangements in BRCA1/BRCA2.
Sahin I; Saat H
Mol Biol Rep; 2021 Jun; 48(6):5057-5062. PubMed ID: 34146199
[TBL] [Abstract][Full Text] [Related]
37. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
Egeli U; Cecener G; Tunca B; Tasdelen I
Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
[TBL] [Abstract][Full Text] [Related]
39. The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel.
Bernstein-Molho R; Laitman Y; Schayek H; Reish O; Lotan S; Haim S; Zidan J; Friedman E
Breast Cancer Res Treat; 2018 Feb; 167(3):697-702. PubMed ID: 29086229
[TBL] [Abstract][Full Text] [Related]
40. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
